- This event has passed.
CRCM
Jun 28 • 8:02 PM
“Maybe the Best Thing That Happened Is That Didn’t Work Out”: Alan Sandler on Daraxonrasib
Key Insights from ASCO Breakthrough 2026 with Julie Gralow
What Really Killed Napoleon? The Autopsy Evidence Behind His Gastric Cancer Diagnosis
Cancer Survivors on How Immunotherapy Saved Their Lives and the Critical Need for Research Funding
25 Posts Not To Miss from MASCC 2026
FDA Approves Sacituzumab Govitecan Plus Pembrolizumab for First-Line PD-L1–Positive TNBC
Radiotherapy in Sudan: Cancer Care Under Pressure From Infrastructure Gaps and Armed Conflict
Discussions Around Retraction of Debated Study on Early Morning Immunotherapy Benefits
